[1]
and
M.C. McCormick, The Contribution of Low Birth Weight to Infant Mortality
Childhood
Morbidity,
N.
Engl.
J.
Med.
312
(1985)
82–90.
https://doi.org/10.1056/NEJM198501103120204.
[2]
L.W. Doyle, S. Rogerson, S. Chuang, M. James, E.D. Bowman, P.G. Davis,
Why do preterm infants die in the 1990s?, Med. J. Aust. 170 (1999) 528–532.
https://doi.org/10.5694/j.1326-5377.1999.tb127877.x.
[3]
周 産 期 ⺟ ⼦ 医 療 セ ン タ ー ネ ッ ト ワ ー ク デ ー タ ベ ー ス , (n.d.).
http://plaza.umin.ac.jp/nrndata/.
[4]
O. Finnström, P.O. Olausson, G. Sedin, F. Serenius, N. Svenningsen, K.
Thiringer, R. Tunell, G. Wesström, Neurosensory outcome and growth at three years in
extremely low birthweight infants: follow-up results from the Swedish national
prospective
study,
Acta
Paediatr.
87
(1998)
1055–1060.
https://doi.org/10.1080/080352598750031374.
[5]
S. Saigal, L. den Ouden, D. Wolke, L. Hoult, N. Paneth, D.L. Streiner, A.
Whitaker, J. Pinto-Martin, School-Age Outcomes in Children Who Were Extremely Low
Birth Weight From Four International Population-Based Cohorts, Pediatrics. 112 (2003)
47
943–950. https://doi.org/10.1542/peds.112.4.943.
[6]
M.S. Kramer, The Contribution of Mild and Moderate Preterm Birth to Infant
Mortality, JAMA. 284 (2000) 843. https://doi.org/10.1001/jama.284.7.843.
[7]
S.B. Morse, H. Zheng, Y. Tang, J. Roth, Early School-Age Outcomes of Late
Preterm Infants, Pediatrics. 123 (2009) e622–e629. https://doi.org/10.1542/peds.20081405.
[8]
C.L.J. Huddy, Educational and behavioural problems in babies of 32-35 weeks
gestation, Arch. Dis. Child. - Fetal Neonatal Ed. 85 (2001) 23F – 28.
https://doi.org/10.1136/fn.85.1.F23.
[9]
of
R.L. Goldenberg, J.F. Culhane, J.D. Iams, R. Romero, Epidemiology and causes
preterm
birth.,
Lancet
(London,
England).
371
(2008)
75–84.
https://doi.org/10.1016/S0140-6736(08)60074-4.
[10]
B.M. Mercer, R.L. Goldenberg, P.J. Meis, A.H. Moawad, C. Shellhaas, A. Das,
M.K. Menard, S.N. Caritis, G.R. Thurnau, M.P. Dombrowski, M. Miodovnik, J.M.
Roberts, D. McNellis, The Preterm Prediction Study: Prediction of preterm premature
rupture of membranes through clinical findings and ancillary testing, Am. J. Obstet.
Gynecol. 183 (2000) 738–745. https://doi.org/10.1067/mob.2000.106766.
[11]
R. Romero, R. Quintero, E. Oyarzun, Y.K. Wu, V. Sabo, M. Mazor, J.C.
48
Hobbins, Intraamniotic infection and the onset of labor in preterm premature rupture of
the
membranes,
Am.
J.
Obstet.
Gynecol.
159
(1988)
661–666.
https://doi.org/10.1016/S0002-9378(88)80030-9.
[12]
J.P. Buyon, M.Y. Kim, M.M. Guerra, C.A. Laskin, M. Petri, M.D. Lockshin, L.
Sammaritano, D.W. Branch, T.F. Porter, A. Sawitzke, J.T. Merrill, M.D. Stephenson, E.
Cohn, L. Garabet, J.E. Salmon, Predictors of pregnancy outcomes in patients with lupus:
A cohort study, Ann. Intern. Med. 163 (2015) 153–163. https://doi.org/10.7326/M142235.
[13]
S.Y. Yuen, A. Krizova, J.M. Ouimet, J.E. Pope, Pregnancy outcome in systemic
lupus erythematosus (SLE) is improving: Results from a case control study and literature
review,
Open
Rheumatol.
J.
(2009)
89–98.
https://doi.org/10.2174/1874312900802010089.
[14]
C.J.F. Smith, F. Förger, G. Bandoli, C.D. Chambers, Factors associated with
preterm delivery among women with rheumatoid arthritis and women with juvenile
idiopathic
arthritis,
Arthritis
Care
Res.
71
(2019)
1019–1027.
https://doi.org/10.1002/acr.23730.
[15]
H. Shimada, R. Wakiya, K. Kanenishi, N. Miyatake, S. Nakashima, M.M.F.
Mansour, M. Kato, T. Miyagi, K. Sugihara, Y. Ushio, R. Mino, M. Mizusaki, T. Kameda,
49
N. Kadowaki, H. Dobashi, Preterm birth is strongly affected by the glucocorticoid dose
during pregnancy in women complicated by systemic lupus erythematosus, Arthritis Res.
Ther. 24 (2022) 10. https://doi.org/10.1186/s13075-021-02699-1.
[16]
M.E.B. Clowse, M. Jamison, E. Myers, A.H. James, A national study of the
complications of lupus in pregnancy, Am. J. Obstet. Gynecol. 199 (2008) 127.e1–127.e6.
https://doi.org/10.1016/j.ajog.2008.03.012.
[17]
E.F. Chakravarty, I. Colón, E.S. Langen, D.A. Nix, Y.Y. El-Sayed, M.C.
Genovese, M.L. Druzin, Factors that predict prematurity and preeclampsia in
pregnancies that are complicated by systemic lupus erythematosus, Am. J. Obstet.
Gynecol. 192 (2005) 1897–1904. https://doi.org/10.1016/j.ajog.2005.02.063.
[18]
C.A. Clark, K.A. Spitzer, J.N. Nadler, C.A. Laskin, Preterm deliveries in
women with systemic lupus erythematosus, J. Rheumatol. 30 (2003) 2127–2132.
[19]
T. Murata, H. Kyozuka, T. Fukuda, S. Yasuda, A. Yamaguchi, A. Sato, Y. Ogata,
M. Kuse, M. Hosoya, S. Yasumura, K. Hashimoto, H. Nishigori, K. Fujimori, Risk of
adverse obstetric outcomes in Japanese women with systemic lupus erythematosus: The
Japan Environment and Children’s Study, PLoS One. 15 (2020) e0233883.
https://doi.org/10.1371/journal.pone.0233883.
[20]
K. Kolstad, J. Mayo, L. Chung, Y. Chaichian, V. Kelly, M. Druzin, D. Stevenson,
50
G. Shaw, J. Simard, Preterm birth phenotypes in women with autoimmune rheumatic
diseases: A population-based cohort study, BJOG An Int. J. Obstet. Gynaecol. 127
(2020) 70–78. https://doi.org/10.1111/1471-0528.15970.
[21]
D.E.A. Pastore, M.L. Costa, F.G. Surita, Systemic lupus erythematosus and
pregnancy: The challenge of improving antenatal care and outcomes, Lupus. 28 (2019)
1417–1426. https://doi.org/10.1177/0961203319877247.
[22]
R. Fischer-Betz, C. Specker, Pregnancy in systemic lupus erythematosus and
antiphospholipid syndrome, Best Pract. Res. Clin. Rheumatol. 31 (2017) 397–414.
https://doi.org/10.1016/j.berh.2017.09.011.
[23]
G. Ekman-Ordeberg, A. Dubicke, Preterm cervical ripening in humans, Facts
Views Vis. ObGyn. 4 (2012) 245–53. http://www.ncbi.nlm.nih.gov/pubmed/24753916.
[24]
M.S. Magid, C. Kaplan, L.R. Sammaritano, M. Peterson, M.L. Druzin, M.D.
Lockshin, Placental pathology in systemic lupus erythematosus: A prospective study,
Am. J. Obstet. Gynecol. 179 (1998) 226–234. https://doi.org/10.1016/S00029378(98)70277-7.
[25]
H. Kiyokawa, H. Mogami, Y. Ueda, Y. Kawamura, M. Sato, Y. Chigusa, M.
Mandai, E. Kondoh, Maternal glucocorticoids make the fetal membrane thinner:
Involvement of amniotic macrophages, Endocrinology. 160 (2019) 925–937.
51
https://doi.org/10.1210/en.2018-01039.
[26]
S. Guller, L. Kong, R. Wozniak, C.J. Lockwood, Reduction of extracellular
matrix protein expression in human amnion epithelial cells by glucocorticoids: A
potential role in preterm rupture of the fetal membranes, J. Clin. Endocrinol. Metab. 80
(1995) 2244–2250. https://doi.org/10.1210/jcem.80.7.7608287.
[27]
S. Guller, R. Wozniak, G. Krikun, J.M. Burnham, P. Kaplan, C.J. Lockwood,
Glucocorticoid suppression of human placental fibronectin expression: implications in
uterine-placental
adherence,
Endocrinology.
133
(1993)
1139–1146.
https://doi.org/10.1210/endo.133.3.8365358.
[28]
K. Kobayashi, I. Kadohira, M. Tanaka, Y. Yoshimura, K. Ikeda, M. Yasui,
Expression and distribution of tight junction proteins in human amnion during late
pregnancy, Placenta. 31 (2010) 158–162. https://doi.org/10.1016/j.placenta.2009.11.014.
[29]
D. Kumar, E. Springel, R.M. Moore, B.M. Mercer, E. Philipson, J.M. Mansour,
S. Mesiano, F. Schatz, C.J. Lockwood, J.J. Moore, Progesterone inhibits in vitro fetal
membrane weakening, Am. J. Obstet. Gynecol. 213 (2015) 520.e1–520.e9.
https://doi.org/10.1016/j.ajog.2015.06.014.
[30]
W. Marinello, L. Feng, T.K. Allen, Progestins inhibit interleukin-1β-induced
matrix metalloproteinase 1 and interleukin 8 expression via the glucocorticoid receptor
52
in primary human amnion mesenchymal cells, Front. Physiol. 11 (2020) 900.
https://doi.org/10.3389/fphys.2020.00900.
[31]
S.G. Lencki, M.B. Maciulla, G.S. Eglinton, Maternal and umbilical cord serum
interleukin levels in preterm labor with clinical chorioamnionitis, Am. J. Obstet.
Gynecol. 170 (1994) 1345–1351. https://doi.org/10.1016/S0002-9378(94)70154-7.
[32]
C.J. Kim, R. Romero, P. Chaemsaithong, N. Chaiyasit, B.H. Yoon, Y.M. Kim,
Acute chorioamnionitis and funisitis: definition, pathologic features, and clinical
significance,
Am.
J.
Obstet.
Gynecol.
213
(2015)
S29–S52.
https://doi.org/10.1016/j.ajog.2015.08.040.
[33]
C. Bombardier, D.D. Gladman, M.B. Urowitz, D. Caron, C.H. Chang, A. Austin,
A. Bell, D.A. Bloch, P.N. Corey, J.L. Decker, J. Esdaile, J.F. Fries, E.M. Ginzler, C.H.
Goldsmith, M.C. Hochberg, J. V. Jones, N.G.H. Le Riche, M.H. Liang, M.D. Lockshin,
L.R. Muenz, D.L. Sackett, P.H. Schur, Derivation of the SLEDAI. A disease activity
index for lupus patients. The Committee on Prognosis Studies in SLE, Arthritis Rheum.
35 (1992) 630–640. https://doi.org/10.1002/art.1780350606.
[34]
A. Fanouriakis, M. Kostopoulou, A. Alunno, M. Aringer, I. Bajema, J.N.
Boletis, R. Cervera, A. Doria, C. Gordon, M. Govoni, F. Houssiau, D. Jayne, M.
Kouloumas, A. Kuhn, J.L. Larsen, K. Lerstrøm, G. Moroni, M. Mosca, M. Schneider,
53
J.S. Smolen, E. Svenungsson, V. Tesar, A. Tincani, A. Troldborg, R. van Vollenhoven, J.
Wenzel, G. Bertsias, D.T. Boumpas, 2019 update of the EULAR recommendations for
the management of systemic lupus erythematosus, Ann. Rheum. Dis. 78 (2019) 736–
745. https://doi.org/10.1136/annrheumdis-2019-215089.
[35]
M. Linette Casey, P.C. MacDonald, Interstitial collagen synthesis and
processing in human amnion: A property of the mesenchymal cells, Biol. Reprod. 55
(1996) 1253–1260. https://doi.org/10.1095/biolreprod55.6.1253.
[36]
U. Kamiya, Bioequivalence study of DECADRON TABLETS 4 mg on healthy
adults,
Shinryo
to
Shinyaku.
51
(2014)
244–250.
https://www.shinryo-to-
shinyaku.com/db/pdf/sin_0051_03_0244.pdf.
[37]
Y. Harahap, L. Sasongko, B. Prasaja, E. Indriati, W. Lusthom, Lipin,
Comparative bioavailability of two dexamethasone tablet formulations in Indonesian
healthy volunteers, Arzneimittelforschung. 59 (2009) 191–4. https://doi.org/10.1055/s0031-1296384.
[38]
A.A. Goyeneche, R.W. Carón, C.M. Telleria, Mifepristone inhibits ovarian
cancer cell growth in vitro and in vivo, Clin. Cancer Res. 13 (2007) 3370–3379.
https://doi.org/10.1158/1078-0432.CCR-07-0164.
[39]
T.W. von Geldern, N. Tu, P.R. Kym, J.T. Link, H.-S. Jae, C. Lai, T. Apelqvist,
54
P. Rhonnstad, L. Hagberg, K. Koehler, M. Grynfarb, A. Goos-Nilsson, J. Sandberg, M.
Österlund, T. Barkhem, M. Höglund, J. Wang, S. Fung, D. Wilcox, P. Nguyen, C. Jakob,
C. Hutchins, M. Färnegårdh, B. Kauppi, L. Öhman, P.B. Jacobson, Liver-selective
glucocorticoid antagonists: A novel treatment for type 2 siabetes, J. Med. Chem. 47
(2004) 4213–4230. https://doi.org/10.1021/jm0400045.
[40]
F. Kielgast, H. Schmidt, P. Braubach, V.E. Winkelmann, K.E. Thompson, M.
Frick, P. Dietl, O.H. Wittekindt, Glucocorticoids regulate tight junction permeability of
lung epithelia by modulating claudin 8, Am. J. Respir. Cell Mol. Biol. 54 (2016) 707–
717. https://doi.org/10.1165/rcmb.2015-0071OC.
[41]
C.R. Keese, K. Bhawe, J. Wegener, I. Giaever, Real-time impedance assay to
follow the invasive activities of metastatic cells in culture, Biotechniques. 33 (2002)
842–850. https://doi.org/10.2144/02334rr01.
[42]
P.M. Becker, A.D. Verin, M.A. Booth, F. Liu, A. Birukova, J.G.N. Garcia,
Differential regulation of diverse physiological responses to VEGF in pulmonary
endothelial cells, Am. J. Physiol. - Lung Cell. Mol. Physiol. 281 (2001) 1500–1511.
https://doi.org/10.1152/ajplung.2001.281.6.l1500.
[43]
S. Kovaka, A. V. Zimin, G.M. Pertea, R. Razaghi, S.L. Salzberg, M. Pertea,
Transcriptome assembly from long-read RNA-seq alignments with StringTie2, Genome
55
Biol. 20 (2019) 278. https://doi.org/10.1186/s13059-019-1910-1.
[44]
M. Pertea, D. Kim, G.M. Pertea, J.T. Leek, S.L. Salzberg, Transcript-level
expression analysis of RNA-seq experiments with HISAT, StringTie and Ballgown, Nat.
Protoc. 11 (2016) 1650–1667. https://doi.org/10.1038/nprot.2016.095.
[45]
prepDE, (n.d.). http://ccb.jhu.edu/software/stringtie/dl/prepDE.py3.
[46]
J. Sun, T. Nishiyama, K. Shimizu, K. Kadota, TCC: An R package for
comparing tag count data with robust normalization strategies, BMC Bioinformatics. 14
(2013) 219. https://doi.org/10.1186/1471-2105-14-219.
[47]
K. Bircher, A.E. Ehret, D. Spiess, M. Ehrbar, A.P. Simões-Wüst, N.
Ochsenbein-Kölble, R. Zimmermann, E. Mazza, On the defect tolerance of fetal
membranes, Interface Focus. 9 (2019) 20190010. https://doi.org/10.1098/rsfs.2019.0010.
[48]
S.E. Calvin, M.L. Oyen, Microstructure and mechanics of the chorioamnion
membrane with an emphasis on fracture properties, Ann. N. Y. Acad. Sci. 1101 (2007)
166–185. https://doi.org/10.1196/annals.1389.009.
[49]
M.L. Oyen, S.E. Calvin, D. V Landers, Premature rupture of the fetal
membranes: is the amnion the major determinant?, Am. J. Obstet. Gynecol. 195 (2006)
510–515. https://doi.org/10.1016/j.ajog.2006.02.010.
[50]
S. Parry, J.F. Strauss, Premature rupture of the fetal membranes, N. Engl. J. Med.
56
338 (1998) 663–670. https://doi.org/10.1056/NEJM199803053381006.
[51]
Y. Okazaki, Gene expression analysis of human amnion mesenchymal cells
treated with dexamethasone, Array Express. Depos. 28 August 2020. (n.d.).
http://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-9493.
[52]
scarring
F. Bouzeghrane, α8β1 integrin is upregulated in myofibroblasts of fibrotic and
myocardium,
J.
Mol.
Cell.
Cardiol.
36
(2004)
343–353.
https://doi.org/10.1016/j.yjmcc.2003.11.007.
[53]
D. Levine, D.C. Rockey, T.A. Milner, J.M. Breuss, J.T. Fallon, L.M. Schnapp,
Expression of the integrin α8β1 during pulmonary and hepatic fibrosis, Am. J. Pathol.
156 (2000) 1927–1935. https://doi.org/10.1016/S0002-9440(10)65066-3.
[54]
A. Hartner, H. Schöcklmann, F. Pröls, U. Müller, R.B. Sterzel, α8 integrin in
glomerular mesangial cells and in experimental glomerulonephritis, Kidney Int. 56
(1999) 1468–1480. https://doi.org/10.1046/j.1523-1755.1999.00662.x.
[55]
J.P. Dhar, L.M. Essenmacher, J.W. Ager, R.J. Sokol, Pregnancy outcomes
before and after a diagnosis of systemic lupus erythematosus, Am. J. Obstet. Gynecol.
193 (2005) 1444–1455. https://doi.org/10.1016/j.ajog.2005.02.104.
[56]
M.A. Boivin, D. Ye, J.C. Kennedy, R. Al-Sadi, C. Shepela, T.Y. Ma, Mechanism
of glucocorticoid regulation of the intestinal tight junction barrier, Am. J. Physiol. Liver
57
Physiol. 292 (2007) G590–G598. https://doi.org/10.1152/ajpgi.00252.2006.
[57]
different
R. Zargham, Tensegrin in context: Dual role of α8 integrin in the migration of
cell
types,
Cell
Adh.
Migr.
(2010)
485–490.
https://doi.org/10.4161/cam.4.4.12403.
[58]
K. Short, F. Wiradjaja, I. Smyth, Let’s stick together: The role of the Fras1 and
Frem proteins in epidermal adhesion, IUBMB Life. 59 (2007) 427–435.
https://doi.org/10.1080/15216540701510581.
[59]
B. Bieritz, P. Spessotto, A. Colombatti, A. Jahn, F. Prols, A. Hartner, Role of α8
integrin in mesangial cell adhesion, migration, and proliferation, Kidney Int. 64 (2003)
119–127. https://doi.org/10.1046/j.1523-1755.2003.00057.x.
[60]
E. Farias, M. Lu, X. Li, L.M. Schnapp, Integrin α8β1–fibronectin interactions
promote cell survival via PI3 kinase pathway, Biochem. Biophys. Res. Commun. 329
(2005) 305–311. https://doi.org/10.1016/j.bbrc.2005.01.125.
[61]
A. Hartner, I. Marek, N. Cordasic, C. Haas, H. Schocklmann, G. Hulsmann-
Volkert, I. Plasa, W. Rascher, K.F. Hilgers, K. Amann, Glomerular regeneration is
delayed in nephritic α8-integrin-deficient mice: Contribution of α8-Integrin to the
regulation of mesangial cell apoptosis, Am. J. Nephrol. 28 (2008) 168–178.
https://doi.org/10.1159/000110022.
58
[62]
G. Volkert, A. Jahn, C. Dinkel, F. Fahlbusch, C. Zürn, K.F. Hilgers, W. Rascher,
A. Hartner, I. Marek, Contribution of the α8 integrin chain to the expression of
extracellular matrix components, Cell Commun. Adhes. 21 (2014) 89–98.
https://doi.org/10.3109/15419061.2013.876012.
[63]
E. Maymon, R. Romero, P. Pacora, M.-T. Gervasi, K. Bianco, F. Ghezzi, B.H.
Yoon, Evidence for the participation of interstitial collagenase (matrix metalloproteinase
1) in preterm premature rupture of membranes, Am. J. Obstet. Gynecol. 183 (2000) 914–
920. https://doi.org/10.1067/mob.2000.108879.
[64]
E. Maymon, R. Romero, P. Pacora, R. Gomez, N. Athayde, S. Edwin, B.H.
Yoon, Human neutrophil collagenase (matrix metalloproteinase 8) in parturition,
premature rupture of the membranes, and intrauterine infection, Am. J. Obstet. Gynecol.
183 (2000) 94–99. https://doi.org/10.1067/mob.2000.105344.
[65]
H. Ender Soydinc, M.E. Sak, O. Evliyaoglu, M.S. Evsen, A. Turgut, A. Ozler,
H.T. Gul, T. Gul, Maternal plasma prolidase, matrix metalloproteinases 1 and 13, and
oxidative stress levels in pregnancies complicated by preterm premature rupture of the
membranes and chorioamnionitis, J. Turkish Ger. Gynecol. Assoc. 13 (2012) 172–177.
https://doi.org/10.5152/jtgga.2012.23.
[66]
S.A. Eming, P. Martin, M. Tomic-Canic, Wound repair and regeneration:
59
Mechanisms, signaling, and translation, Sci. Transl. Med. 6 (2014) 265sr6–265sr6.
https://doi.org/10.1126/scitranslmed.3009337.
[67]
V. Serpooshan, M. Zhao, S.A. Metzler, K. Wei, P.B. Shah, A. Wang, M.
Mahmoudi, A. V. Malkovskiy, J. Rajadas, M.J. Butte, D. Bernstein, P. Ruiz-Lozano, The
effect of bioengineered acellular collagen patch on cardiac remodeling and ventricular
function
post
myocardial
infarction,
Biomaterials.
34
(2013)
9048–9055.
https://doi.org/10.1016/j.biomaterials.2013.08.017.
[68]
K. Wei, V. Serpooshan, C. Hurtado, M. Diez-Cuñado, M. Zhao, S. Maruyama,
W. Zhu, G. Fajardo, M. Noseda, K. Nakamura, X. Tian, Q. Liu, A. Wang, Y. Matsuura,
P. Bushway, W. Cai, A. Savchenko, M. Mahmoudi, M.D. Schneider, M.J.B. van den
Hoff, M.J. Butte, P.C. Yang, K. Walsh, B. Zhou, D. Bernstein, M. Mercola, P. RuizLozano, Epicardial FSTL1 reconstitution regenerates the adult mammalian heart, Nature.
525 (2015) 479–485. https://doi.org/10.1038/nature15372.
[69]
B.M. Sicari, J.P. Rubin, C.L. Dearth, M.T. Wolf, F. Ambrosio, M. Boninger, N.J.
Turner, D.J. Weber, T.W. Simpson, A. Wyse, E.H.P. Brown, J.L. Dziki, L.E. Fisher, S.
Brown, S.F. Badylak, An acellular biologic scaffold promotes skeletal muscle formation
in mice and humans with volumetric muscle loss, Sci. Transl. Med. 6 (2014) 234ra58–
234ra58. https://doi.org/10.1126/scitranslmed.3008085.
60
[70]
M.P. Lutolf, J.A. Hubbell, Synthetic biomaterials as instructive extracellular
microenvironments for morphogenesis in tissue engineering, Nat. Biotechnol. 23 (2005)
47–55. https://doi.org/10.1038/nbt1055.
[71]
F. Berthiaume, T.J. Maguire, M.L. Yarmush, Tissue engineering and
regenerative medicine: History, progress, and challenges, Annu. Rev. Chem. Biomol.
Eng. 2 (2011) 403–430. https://doi.org/10.1146/annurev-chembioeng-061010-114257.
[72]
H. Mogami, A.H. Kishore, R.A. Word, Collagen type 1 accelerates healing of
ruptured fetal membranes, Sci. Rep. 8 (2018) 1–9. https://doi.org/10.1038/s41598-01718787-9.
[73]
A.F. Borgida, A.A. Mills, D.M. Feldman, J.F. Rodis, J.F.X. Egan, Outcome of
pregnancies complicated by ruptured membranes after genetic amniocentesis, Am. J.
Obstet. Gynecol. 183 (2000) 937–939. https://doi.org/10.1067/mob.2000.108872.
[74]
that
J.W. C. Johnson, R.S. Egerman, J. Moorhead, Cases with ruptured membranes
“reseal,”
Am.
J.
Obstet.
Gynecol.
163
(1990)
1024–1030.
https://doi.org/10.1016/0002-9378(90)91117-U.
[75]
R.F. van Vollenhoven, M. Mosca, G. Bertsias, D. Isenberg, A. Kuhn, K.
Lerstrøm, M. Aringer, H. Bootsma, D. Boumpas, I.N. Bruce, R. Cervera, A. Clarke, N.
Costedoat-Chalumeau, L. Czirják, R. Derksen, T. Dörner, C. Gordon, W. Graninger, F.
61
Houssiau, M. Inanc, S. Jacobsen, D. Jayne, A. Jedryka-Goral, A. Levitsky, R. Levy, X.
Mariette, E. Morand, S. Navarra, I. Neumann, A. Rahman, J. Rovenský, J. Smolen, C.
Vasconcelos, A. Voskuyl, A. Voss, H. Zakharova, A. Zoma, M. Schneider, Treat-totarget in systemic lupus erythematosus: recommendations from an international task
force, Ann. Rheum. Dis. 73 (2014) 958–967. https://doi.org/10.1136/annrheumdis2013-205139.
[76]
L. Andreoli, G.K. Bertsias, N. Agmon-Levin, S. Brown, R. Cervera, N.
Costedoat-Chalumeau, A. Doria, R. Fischer-Betz, F. Forger, M.F. Moraes-Fontes, M.
Khamashta, J. King, A. Lojacono, F. Marchiori, P.L. Meroni, M. Mosca, M. Motta, M.
Ostensen, C. Pamfil, L. Raio, M. Schneider, E. Svenungsson, M. Tektonidou, S. Yavuz,
D. Boumpas, A. Tincani, EULAR recommendations for women’s health and the
management of family planning, assisted reproduction, pregnancy and menopause in
patients with systemic lupus erythematosus and/or antiphospholipid syndrome, Ann.
Rheum. Dis. 76 (2017) 476–485. https://doi.org/10.1136/annrheumdis-2016-209770.
[77]
D.J. Wallace, H.Bevra, Dubois’ Lupus Erythematosus and Related Syndromes,
9th ed., Elsevier, Edinburgh, 2019.
62
謝辞
本研究と論文作成にあたり、ご指導、ご高閲を賜りました谷口公介先生、中
林一彦先生および秦健一郎先生（国立成育医療研究センター周産期病態研究部）
宮本義孝先生(国立成育医療研究センター再生医療センター・細胞医療研究部)、
木下史織様（国立成育医療研究センター周産期病態研究部）、金子佳代子先生、
村島温子先生(国立成育医療研究センター周産期・母性診療センター母性内科)、
そして国立成育医療研究センター周産期病態研究部および周産期・母性診療セ
ンターの皆様に心から感謝いたします。また研究を開始するにあたり多大なる
ご助言をいただきました最上晴太先生(京都大学医学部婦人科学産科学教室)、
統計解析のご指導をいただきました三上剛史先生(国立成育医療研究センター
臨床研究センターデータサイエンス部門)、永田知映先生(国立成育医療研究セ
ンター教育研修センター教育研修室)、事務的手続きで大変お世話になりました
高貝マリコ様(国立成育医療研究センター周産期・母性診療センター母性内科)、
ご助言をいただいた濱田洋実教授(筑波大学医学医療系産科婦人科学)、佐藤豊
実教授(筑波大学医学医療系産科婦人科学)に深謝いたします。
63
...
論文の公開元へ
